25134-54-7|F 522|2-(dimethylamino)ethyl methacrylate compound with ethene (11)|-范德生物科技公司

F 522

NMR下载 COA and HPLC MSDS下载
names：
2-(dimethylamino)ethyl methacrylate compound with ethene (11)
CAS号：
25134-54-7
MDL Number：
MF(分子式)： C10H19NO2 MW(分子量)： 185.27
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	F 522
英文别名	F 522; DA 1701; DA 3023; DA 3031;F522; F-522; Sumiepoch F 522;
CAS号	25134-54-7
SMILES	C(C(=C)C)(=O)OCCN(C)C.C=C
Inchi	InChI=1S/C8H15NO2.C2H4/c1-7(2)8(10)11-6-5-9(3)4;1-2/h1,5-6H2,2-4H3;1-2H2
InchiKey	PNMYDOBPCBCQIA-UHFFFAOYSA-N
分子式 Formula	C10H19NO2
分子量 Molecular Weight	185.27
闪点 FP
熔点 Melting point
沸点 Boiling point
Polarizability极化度
密度 Density
蒸汽压 Vapor Pressure
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	F 522(CAS:25134-54-7):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	F 522 is also kown as DA-3031. DA-3031 is a newly developed pegylated filgrastim, a recombinant human granulocyte colony-stimulating factor, that is expected to have an extended duration of action compared with non-modified filgrastim. was developed for prophylactic use in breast cancer.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Ahn LY, Shin KH, Lim KS, Kim TE, Jeon H, Yoon SH, Cho JY, Shin SG, Jang IJ, Yu KS. Relationship between absolute neutrophil count profiles and pharmacokinetics of DA-3031, a pegylated granulocyte colony-stimulating factor (pegylated-G-CSF): a dose block-randomized, double-blind, dose-escalation study in healthy subjects. Clin Drug Investig. 2013 Nov;33(11):817-24. PubMed PMID: 24078278.

[2]Park KH, Sohn JH, Lee S, Park JH, Kang SY, Kim HY, Park IH, Park YH, Im YH, Lee HJ, Hong DS, Park S, Shin SH, Kwon HC, Seo JH. A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer. Invest New Drugs. 2013 Oct;31(5):1300-6. doi: 10.1007/s10637-013-9973-4. Epub 2013 May 16. PubMed PMID: 23677653.

[3] Wadhwa M, Bird C, Dougall T, Rigsby P, Bristow A, Thorpe R; participants of the study. Establishment of the first international standard for PEGylated granulocyte colony stimulating factor (PEG-G-CSF): report of an international collaborative study. J Immunol Methods. 2015 Jan;41

6:17-28. doi: 10.1016/j.jim.2014.10.005. Epub 2014 Oct 25. PubMed PMID: 25450254; PubMed Central PMCID: PMC4334095.

[5] Park KH, Lee S, Park JH, Kang SY, Kim HY, Park IH, Park YH, Im YH, Lee HJ, Park S, Lee SI, Jung KH, Kim YS, Seo JH. A randomized, multi-center, open-label, phase III study of once-per-cycle DA-3031, a pegylated G-CSF, in comparison with daily filgrastim in patients receiving TAC chemotherapy for breast cancer. Support Care Cancer. 2017 Feb;25(2):505-511. doi: 10.1007/s00520-016-3429-2. Epub 2016 Oct 6. PubMed PMID: 27709313.

5: Kam G, Yiu R, Loh Y, Ang AL, Yueh LL, Goh YT, Wong GC. Impact of pegylated filgrastim in comparison to filgrastim for patients with acute myeloid leukaemia (AML) on high-dose cytarabine (HIDAC) consolidation chemotherapy. Support Care Cancer. 2015 Mar;23(3):643-9. doi: 10.1007/s00520-014-2417-7. Epub 2014 Aug 27. PubMed PMID: 25160495.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开